Back to Journals » Psoriasis: Targets and Therapy » Volume 8

Targeting IL-23 in psoriasis: current perspectives

Authors Fotiadou C, Lazaridou E, Sotiriou E, Ioannides D

Received 24 July 2017

Accepted for publication 28 November 2017

Published 4 January 2018 Volume 2018:8 Pages 1—5

DOI https://doi.org/10.2147/PTT.S98893

Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Dr Colin Mak

Peer reviewer comments 2

Editor who approved publication: Professor Uwe Wollina


Christina Fotiadou, Elizabeth Lazaridou, Eleni Sotiriou, Demetrios Ioannides

First Department of Dermatology and Venereology, Aristotle University Medical School, Thessaloniki, Greece

Abstract: The recent advances in the understanding of psoriasis pathogenesis have clarified the pivotal role of interleukin (IL)-23. It is a heterodimeric cytokine consisting of two subunits, the unique p19 and the p40, which are shared with IL-12. The basic role of IL-23 in psoriasis is the activation and maintenance of the T-helper 17 pathway. New research findings indicate that IL-23 is more important than IL-12 in the pathogenesis of psoriasis. Based on that background, the selective targeting of the IL-23p19 subunit emerged as an attractive therapeutic option and led to the development of a new category of biologic agents. Three monoclonal antibodies that selectively inhibit the IL-23p19 subunit, guselkumab, tildrakizumab, and risankizumab, are in the pipeline for the treatment of moderate-to-severe psoriasis. In this article, we review the most recent efficacy and safety data regarding these IL-23p19 inhibitors.

Keywords: psoriasis, IL-23, treatment, Th17 axis, anti-IL-23p19 monoclonal antibodies

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]